Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab ; volume:7 ; number:3 ; day:21 ; month:2 ; year:2005 ; pages:1-6 ; date:3.2005
Arthritis Research & Therapy ; 7, Heft 3 (21.2.2005), 1-6, 3.2005
- Creator
- Contributor
-
Listing, Joachim
Brandt, Jan
Rudwaleit, Martin
Sieper, Joachim
Braun, Juergen
SpringerLink (Online service)
- DOI
-
10.1186/ar1693
- URN
-
urn:nbn:de:1111-201605032315
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Baraliakos, Xenofon
- Listing, Joachim
- Brandt, Jan
- Rudwaleit, Martin
- Sieper, Joachim
- Braun, Juergen
- SpringerLink (Online service)
Other Objects (12)
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis
The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study
Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment
Body mass index influences the response to infliximab in ankylosing spondylitis
A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil
Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis
The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study
Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment
Body mass index influences the response to infliximab in ankylosing spondylitis
A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil
Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry
Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis
The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study
Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment
Body mass index influences the response to infliximab in ankylosing spondylitis
A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)
Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil